LOGIN  |  REGISTER
Cue Biopharma
Cue Biopharma

XOMA Royalty to Present at Investor Conferences in March

February 24, 2025 | Last Trade: US$32.47 0.23 -0.70

EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following investor conferences in March.  Management will also participate in one-on-one investor meetings.

T.D. Cowen 45th Annual Health Care Conference (March 3-5, 2025)
Format:
Date:
Time:
Corporate presentation
Monday, March 3, 2025
11:10AM ET
Location:
Link:
Boston, MA
/webcast/cowen177/register.aspx?conf=cowen177&page=xoma&url=https://wsw.com/webcast/cowen177/xoma/2033463
  
Leerink 2025 Global Healthcare Conference (March 9-12, 2025)
Format:Fireside chat
Date:Monday, March 10, 2025
Time:2:20PM ET
Location:
Link:
Miami Beach, FL
/webcast/leerink38/register.aspx?conf=leerink38&page=xoma&url=https://wsw.com/webcast/leerink38/xoma/2233817

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Royalty Corporation

XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact XOMA Media Contact
Juliane SnowdenKathy Vincent
XOMA Royalty  KV Consulting & Management
+1 646-438-9754  +1 310-403-8951
This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page